GlassScriptPhysician profile
William A Liss
NPI 1740368828
$2,695.28
in general payments reported to CMS, 2019-2025
13 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.09 · 2022: $12.06 · 2023: $404 · 2024: $983 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.68 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $818.75 | 2023-2025 | Sotyktu |
| Abbvie INC. | $573.25 | 2024-2025 | |
| Incyte Corporation | $319.29 | 2023-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $304.55 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $227.51 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $116.86 | 2023 | Tremfya |
| Lilly USA, LLC | $111.91 | 2019-2023 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $71.92 | 2024-2025 | |
| Ucb, INC. | $49.17 | 2025 | Bimzelx |
| Genzyme Corporation | $38.05 | 2025 | |
| Dermavant Sciences, INC. | $27.08 | 2023 | Vtama |
| Strata Skin Sciences, INC. | $24.88 | 2025 | Xtrac |
| Journey Medical Corporation | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Liss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.